EDIT vs NTLA
EDIT: A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL receptor upregulation. NTLA: CRISPR-based genome editing company developing in vivo therapies for rare genetic diseases including hereditary angioedema and ATTR amyloidosis.
Side-by-side fundamentals
| Metric | EDIT | NTLA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.78 | $11.13 | |
| Market cap as of 2026-07-23 | $421M | $1.6B | |
| Net margin as of 2026-07-23 | -281.6% | -597.0% | EDIT higher |
| Operating margin as of 2026-07-23 | -281.3% | -636.6% | EDIT higher |
| ROE as of 2026-07-23 | -677.4% | -57.3% | NTLA higher |
| ROA as of 2026-07-23 | -58.3% | -46.1% | NTLA higher |
| Debt / equity as of 2026-07-23 | 12.40 | 0.00 | NTLA lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.0% | +45.0% | NTLA higher |
| Revenue CAGR (3y) SEC XBRL | +27.1% | +9.1% | EDIT higher |
| Beta as of 2026-07-23 | 2.08 | 1.78 | |
| 1-year return as of 2026-07-22 close | -8.3% | -17.5% | EDIT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.